SCHEMBL2122691

SCHEMBL2122691

CCCNC1COCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL8557568 0.96
SCHEMBL9152652 0.87 GNAI3 (0.41)
Hydrazine SCHEMBL8558957 0.84 GNAI3 (0.39)
SCHEMBL7294166 0.73
SCHEMBL4687615 0.73
SCHEMBL8827681 0.70 L3MBTL1 (0.39)
SCHEMBL7518979 0.70 POLB (0.33)
SCHEMBL3644949 0.69
SCHEMBL4829518 0.69
SCHEMBL1854212 0.69 GAA (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113929642-B Dehydroabietylamine silver ion fluorescent probe and preparation method thereof 南京林业大学 2023-04-11 CN claimed
US-10975092-B2 Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2021-04-13 US claimed
US-20200115386-A1 PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF Anhui New Star Pharmaceutical Development Co., Ltd . (CN) 2020-04-16 US claimed
EP-3424929-A1 PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF Anhui New Star Pharmaceutical Development Co., Ltd (CN) 2019-01-09 EP claimed
CN-104080865-B Photoresponse binding agent 湛新比利时股份有限公司 2016-06-08 CN claimed
CN-122029238-A Curable composition and cured product 株式会社钟化 2026-05-12 CN disclosed
CN-104080865-B Photoresponse binding agent 湛新比利时股份有限公司 2016-06-08 CN disclosed
WO-2012051457-A1 NUCLEIC ACID DELIVERY COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-04-19 WO disclosed
US-20120094924-A1 NUCLEIC ACID DELIVERY COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-04-19 US disclosed
US-7998950-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2011-08-16 US disclosed
US-20100022508-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-01-28 US disclosed
US-20060135517-A1 Imidazolopyridines and methods of making and using the same BIOGEN IDEC MA INC. 2006-06-22 US disclosed
WO-2003051897-A1 NUCLEOSIDE ANALOG LIBRARIES AND COMPOUNDS RIBAPHARM INC. (US) 2003-06-26 WO disclosed
WO-2003051896-A1 CYTIDINE LIBRARIES AND COMPOUNDS SYNTHESIZED BY SOLID-PHASE COMBINATORIAL STRATEGIES RIBAPHARM INC. (US) 2003-06-26 WO disclosed
US-20020051991-A1 Rapid generation of diverse nucleoside and nucleotide libraries HONG ZHI (US) 2002-05-02 US disclosed
EP-0575954-B1 Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process MEDIOLANUM FARMACEUTICI SRL (IT) 1998-09-02 EP disclosed
US-5424451-A Used as cholinesterase activity inhibitors MEDIOLANUM FARMACEUTICI S.P.A. (IT) 1995-06-13 US disclosed
US-5302593-A Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors MEDIOLANUM FARMACEUTICI S.P.A. (IT) 1994-04-12 US disclosed
EP-0575954-A1 Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process MEDIOLANUM FARMACEUTICI S.P.A. (IT) 1993-12-29 EP disclosed
EP-0433879-A2 Aminothiazoles BASF Aktiengesellschaft (DE) 1991-06-26 EP disclosed